Completed × Graft vs Host Disease × Plasma cell × Clear all
NCT01350245 2025-05-16

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Thomas Jefferson University

Phase 2 Completed
28 enrolled 10 charts
NCT03128359 2024-01-09

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

City of Hope Medical Center

Phase 2 Completed
38 enrolled 11 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT00096161 2020-01-31

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 13 charts
NCT00003270 2019-12-13

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
NCT00003398 2019-10-17

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 4 Completed
45 enrolled
NCT00001873 2018-09-26

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00005988 2017-04-04

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Dana-Farber Cancer Institute

Phase 1 Completed
5 enrolled
NCT00755040 2017-03-07

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
164 enrolled 8 charts
NCT00079391 2015-10-26

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 12 charts
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00003538 2014-05-02

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase NA Completed
NCT00265837 2014-04-17

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Completed
72 enrolled
NCT01233921 2014-04-02

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase NA Completed
6 enrolled 7 charts
NCT00900406 2012-11-06

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

Completed
190 enrolled
NCT00004904 2012-06-04

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed
NCT00004232 2012-06-01

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed
NCT00089037 2011-07-15

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00361049 2010-11-05

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Case Comprehensive Cancer Center

Phase 1 Completed
49 enrolled
NCT00357084 2010-09-14

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled
NCT00109993 2010-06-11

Campath-1H + FK506 and Methylprednisolone for GVHD

Case Comprehensive Cancer Center

Phase 2 Completed
34 enrolled
NCT00410657 2010-05-14

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled
NCT00096096 2010-05-13

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Completed
NCT00010283 2010-04-02

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00255710 2010-03-17

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
60 enrolled
NCT00001748 2008-03-04

HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled